Highline Wealth Partners LLC Invests $2.05 Million in Danaher Co. (NYSE:DHR)

Highline Wealth Partners LLC bought a new position in shares of Danaher Co. (NYSE:DHR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,384 shares of the conglomerate’s stock, valued at approximately $2,053,000.

Several other large investors have also added to or reduced their stakes in DHR. Benjamin Edwards Inc. boosted its position in shares of Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after purchasing an additional 38 shares during the period. Wedge Capital Management L L P NC boosted its holdings in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares during the period. Patrick M Sweeney & Associates Inc. grew its position in shares of Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after acquiring an additional 40 shares during the last quarter. Trust Co of Kansas raised its position in Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares during the last quarter. Finally, Abacus Planning Group Inc. raised its position in Danaher by 0.7% in the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity

In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Linda Filler sold 3,928 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the transaction, the director now directly owns 41,149 shares in the company, valued at approximately $11,501,145.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,052 shares of company stock worth $5,878,937 over the last three months. 11.10% of the stock is currently owned by corporate insiders.

Danaher Price Performance

Danaher stock opened at $243.12 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm’s 50-day simple moving average is $268.40 and its 200 day simple moving average is $260.55. Danaher Co. has a 52 week low of $188.75 and a 52 week high of $281.70. The firm has a market capitalization of $180.08 billion, a PE ratio of 41.15, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the business earned $2.02 earnings per share. The company’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities research analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research reports. Royal Bank of Canada lowered their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Barclays dropped their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Raymond James lowered their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI upped their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, The Goldman Sachs Group lifted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $287.28.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.